St. Jude Care & Treatment

Menu

Close

Recruiting

CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms

About this study

Some patients treated for cancer or blood diseases may get cancer again. This second cancer may come from the disease or its treatment.

We want to study the effects of a new drug, CPX-351, to treat 2 kinds of secondary cancers:

  • Myelodysplastic syndrome (MDS)
  • Acute myeloid leukemia (AML)

We aim to:

  • Study how well CPX-351 treats MDS and AML
  • Learn more about the side effects of CPX-351
  • Learn more about how the body reacts to CPX-351
  • Learn more about the biology and genetics of patients with MDS and AML

In this study patients will be treated with:

  • 2 rounds of CPX-351

A stem cell transplant or other therapies may follow this treatment. We will study DNA changes in your bone marrow and blood.

Eligibility overview

To take part in this study, patients must:

  • Be 1–22 years old
  • Have 1 of the following:
    • MDS or AML as a second cancer
    • MDS or AML that was caused by earlier treatments
  • Pass tests for kidney, liver, heart, brain, and spinal cord function
  • Have recovered from earlier treatments

Patients are not eligible for this study if they are:

  • Taking another new drug as part of a research study
  • Taking medicine for a heart problem known as left ventricular systolic dysfunction
  • Pregnant or breastfeeding

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms 

Study goal:

This study will help us understand the effects of CPX-351 treatment in patients with MDS and AML.

Diagnosis:

Acute myeloid leukemia, myelodysplastic syndromes

Age:

1-22 years old

Clinical trials categories:

Blood Disorders Acute Myeloid Leukemia (AML) Childhood Cancer Leukemia Myelodysplastic Syndromes

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more